We are a biopharmaceutical company focused on discovering, developing and commercializing innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We seek to apply new and proprietary formulations and delivery methods to existing pharmaceutical compounds in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development program is based on existing compounds with known safety, efficacy and commercialization histories. We believe this will increase the likelihood of success for our drug development and commercialization efforts. Our goal is to leverage our expertise in the expanding fields of synthetic cannabinoid derivatives and specialized opioid therapies to build a portfolio of proprietary products that address the limitations of existing treatments.